Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4838943 | 0.92 | HRH3 (0.45) | TLR7HRH3HRH2HRH1HRH4 | |
| SCHEMBL6246858 | 0.86 | HRH3 (0.42) | TLR7HRH3HRH2HRH1HRH4 | |
| SCHEMBL4834847 | 0.86 | LTA4H (0.47) | HRH3HRH2HRH1ACHETBK1 | |
| SCHEMBL4838040 | 0.85 | KMT2A (0.41) | TLR7HRH3HRH4 | |
| SCHEMBL4840409 | 0.84 | ACHE (0.48) | HRH3HRH2HRH1ACHETBK1 | |
| SCHEMBL4834168 | 0.83 | HRH4 (0.46) | HRH4ACHETBK1IKBKE | |
| SCHEMBL4845601 | 0.83 | ACHE (0.48) | HRH3HRH2HRH1ACHETBK1 | |
| SCHEMBL4844406 | 0.83 | ACHE (0.61) | ACHETBK1IKBKE | |
| SCHEMBL4838294 | 0.83 | TBK1 (0.48) | ACHETBK1IKBKE | |
| SCHEMBL4846045 | 0.82 | ACHE (0.52) | HRH4ACHETBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | claimed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TLR7 2395/4885HRH3 430/4885HRH2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.